Comprehensive US stock earnings whisper numbers and actual versus estimate analysis to identify surprises before they happen in the market. Our earnings surprise analysis helps you anticipate positive or negative reactions before the market opens the following day. We provide whisper numbers, estimate trends, and surprise probability analysis for comprehensive earnings coverage. Anticipate earnings moves with our comprehensive surprise analysis and indicators for better earnings trading strategies.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Real Time Stock Idea Network
REGN - Stock Analysis
3474 Comments
1183 Likes
1
Deus
Community Member
2 hours ago
Wish I had caught this before.
👍 230
Reply
2
Baruti
Returning User
5 hours ago
Concise insights that provide valuable context.
👍 244
Reply
3
Claraliz
Legendary User
1 day ago
I feel like there’s a whole community here.
👍 41
Reply
4
Nisiah
Expert Member
1 day ago
I feel like applauding for a week straight. 👏
👍 229
Reply
5
Kyong
New Visitor
2 days ago
Could’ve made use of this earlier.
👍 299
Reply
© 2026 Market Analysis. All data is for informational purposes only.